Antares Pharma (ATRS) Gets a Buy Rating from Piper Jaffray

By Ryan Adsit

In a report issued on August 16, David Amsellem from Piper Jaffray reiterated a Buy rating on Antares Pharma (NASDAQ: ATRS), with a price target of $4. The company’s shares closed yesterday at $3.39.

According to, Amsellem is a 1-star analyst with an average return of -1.9% and a 44.1% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Amphastar Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Antares Pharma with a $4.12 average price target, representing a 21.5% upside. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $4.50 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $4.09 and a one-year low of $1.58. Currently, Antares Pharma has an average volume of 986.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Antares Pharma, Inc. is a pharmaceutical company. The company focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its activities include the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.